// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

SARS-CoV-2: Survival in COPD phenotypes

Matthew Pavitt - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Bacterial Pneumonias: Before and after the COVID-19 pandemic

Khalil Ur Rehman - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Evaluating the accuracy of pulse oximetry: Finger probe versus earlobe probe in patients with confirmed or suspected COVID-19 within the community setting

Emma Rickards - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

ENO breathe: An arts and health alliance to help COVID-19 recovery

Harriet Owles - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Managing COVID-19 illness: chest radiographs support defining both prognosis and follow up

Sadia Ahmed - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Passive Microwave Radiometry (MWR) for diagnostics of COVID-19 lung complications in Kyrgyzstan

Batyr Osmonov - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Severe COVID-19 pneumonia

N/A

Local incidence and outcomes of patients with pneumothorax and pneumomediastinum in COVID-19

Karl Jackson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pneumothorax

N/A

What can we learn about oxygen therapy from the Nightingale North West experience?

Stephanie Stolberg - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

The implementation of routine breathlessness and cough scoring in a virtual early supported discharge service for COVID-19

Katie Rhatigan - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia

Ryan Adams - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Severe COVID-19 pneumonia

N/A

COVID19: a retrospective cohort study in Bradford with a focus on ethnicity

Laura Smith - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Validation of the CFS score in patients with Covid-19 receiving only ward based care

Karl Jackson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

SPAR (Symmetric Projection Attractor Reconstruction): Identifying novel respiratory biomarkers from waveform morphology and variability

Miquel Serna Pascual - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impact of incorporating the evaluation of full inflation recommended in the 2019 spirometry standards on the evaluation of spirometry acceptability

Kevin McCarthy - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

High accuracy of automated respiratory rate readings in a novel, non-contact home monitor

William Do - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Persistent chronic dyspnoea following COVID-19 infection

Neeraj Shah - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Daytime physical activity and sleep quality as related to patient-reported and physiological outcomes following severe COPD exacerbation

Rebecca D’Cruz - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Chronic coronary artery disease and decline of lung function as predictors of mortality and exacerbation risk in stable COPD: Results from COSYCONET

Peter Alter - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Coronary Artery Disease

N/A

Pulmonary function after COVID-19 infection and the impact of disease severity

Max Thomas - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Neural respiratory drive in survivors of severe COVID-19 pneumonitis

Caroline Jolley - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary alveolar proteinosis

N/A

Copyright © 2026. QuantiNova All rights reserved